Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US

  • Continuing operations2 net sales up 13% (cc1, +10% USD) driven by:
    • Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regions
    • Entresto USD 430 million (+61% cc), with increased demand in hospital and ambulatory settings
    • Zolgensma sales of USD 160 million, strong launch including broad access
    • Lutathera sales grew to USD 119 million, total AAA sales were USD 177 million
    • Piqray sales were USD 43 million, off to a strong start …
/by